Related Experiment Videos
[Therapy of chronic hepatitis B with interferon]
1Universitätsklinik für Innere Medizin, Innsbruck.
Wiener Medizinische Wochenschrift (1946)
|January 1, 1993
Summary
Recombinant interferon-alpha (IFN-alpha) effectively treats chronic hepatitis B, achieving remission in 30-40% of patients. Prognostic factors influence treatment response in this viral hepatitis therapy.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Context:
- Chronic hepatitis B is a significant global health concern.
- Recombinant interferon-alpha (IFN-alpha) has emerged as a therapeutic option.
- Previous studies established IFN-alpha efficacy in Europe and North America.
Purpose:
- To summarize the effectiveness of recombinant interferon-alpha (IFN-alpha) for chronic hepatitis B.
- To identify prognostic factors influencing treatment outcomes.
Summary:
- Recombinant IFN-alpha administered subcutaneously for 4-6 months achieves 30-40% remission rates in chronic hepatitis B patients.
- Complete remission involves loss of viral markers; incomplete remission shows hepatitis resolution with persistent markers.
- High hepatitis activity and low viral replication predict favorable outcomes.
Impact:
- Identifies patient groups with lower response rates, including males, childhood infections, and delta virus coinfection.
- Highlights the need for specialized care, including liver transplantation options, for decompensated cirrhotic patients.
- Provides evidence-based insights for optimizing chronic hepatitis B management strategies.